1-butyl-4,5-dimethyl-1H-imidazole | 1172064-50-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-butyl-4,5-dimethyl-1H-imidazole
• 英文别名: 1-butyl-4,5-dimethylimidazole
• CAS: 1172064-50-4
• 化学式: C₉H₁₆N₂
• 分子量: 152.239
• InChiKey: CNIOVXUZRNOZNF-UHFFFAOYSA-N

物化性质

• 沸点：
  283.2±9.0 °C(Predicted)
• 密度：
  0.94±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-butyl-4,5-dimethyl-1H-imidazole 在 lithium diisopropyl amide 、 碘 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以55%的产率得到1-butyl-2-iodo-4,5-dimethyl-1H-imidazole
  参考文献：
  名称：

  Synthesis of optically active polyheterocycles containing pyrrolidine, imidazole, and 1,2,3-triazole rings

  摘要：

  Optically active polyheterocycles containing pyrrolidine, imidazole, and 1,2,3-triazole units were obtained via a multistep synthesis with the [3+2] cycloaddition of Boc-protected (S)-(pyrrolidin-2-yl) methyl azide with 2-ethynylimidazoles in the presence of CuI (CuAAC reaction) as the key step. Typical for terminal alkynes, the reactions occurred regioselectively and 1,4-disubstituted 1,2,3-triazoles were formed exclusively. The deprotection of the pyrrolidine N-atom was performed by treatment with TFA under standard conditions. (c) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2015.10.019
• 作为产物：
  描述：

  1-butyl-4,5-dimethyl-1H-imidazole 3-oxide 在 镍 作用下， 以 乙醇 为溶剂， 以91%的产率得到1-butyl-4,5-dimethyl-1H-imidazole
  参考文献：
  名称：

  Exploration of 4,5-dimethyl-1H-imidazole N-oxide derivatives in the synthesis of new achiral and chiral ionic liquids

  摘要：

  New 1-alkoxy-3-alkyl-4,5-dimethylimidazolium bromides were synthesized by alkylation of the corresponding 1-alkylimidazole 3-oxides, which were conveniently prepared via condensation of alpha-(hydroxyimino)ketones, primary aliphatic amines, and formaldehyde. By using enantiomerically pure chiral amines, optically active imidazolium Salts were obtained. Treatment with sodium tetrafluoroborate in acetone yielded the corresponding imidazolium tetrafluoroborates. All these compounds, with only one exception, were obtained as oils, which are considered as potential ionic liquids and 'chiral ionic liquids'. The reduction of the chiral or non-chiral 1-alkylimidazole 3-oxides with Raney-Ni, followed by alkylation with alkyl bromides and subsequent ion exchange to tetra fluoroborates, gave the corresponding 1,3-dialkylimidazolium salts, most of them showing properties of ionic liquids. The alkylation of 1-butyl-4,5-dimethylimidazole 3-oxide and the corresponding imidazole, respectively, with 1,3-dibromopropane led to the first bis-imidazolium dibromides and bis-tetrafluoroborates. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.02.053

文献信息

• Syntheses of polyalkylated imidazoles
  作者：Sigvart Evjen、Anne Fiksdahl

  DOI：10.1080/00397911.2017.1330416

  日期：2017.8.3

  ABSTRACT We have developed improved general simple methods for large-scale preparation of polyalkylated imidazoles by improved multicomponent synthesis from commercially available starting materials. A large range of NH- and N-alkyl-polyalkylimidazoles (40 in total, including novel compounds) has been synthesized. GRAPHICAL ABSTRACT

  摘要我们已经开发了改进的通用简单方法，通过改进的多组分合成从市售原料大规模制备聚烷基化咪唑。已经合成了多种 NH-和 N-烷基-聚烷基咪唑（共 40 种，包括新型化合物）。图形概要
• HYDROXYL PURINE COMPOUNDS AND USE THEREOF
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：EP3299371A1

  公开（公告）日：2018-03-28

  Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

  公开了一系列羟基嘌呤化合物及其作为 PDE2 或 TNFα 抑制剂的用途，特别是如式 (I) 所示的化合物或其同系物或其药学上可接受的盐。
• Hydroxyl purine compounds and use thereof
  申请人：GUANGDONG RAYNOVENT BIOTECH CO., LTD.

  公开号：US10278973B2

  公开（公告）日：2019-05-07

  Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

  公开了一系列羟基嘌呤化合物及其作为 PDE2 或 TNFα 抑制剂的用途，特别是如式 (I) 所示的化合物或其同系物或其药学上可接受的盐。
• NONLINEAR OPTICAL MATERIALS CONTAINING POLAR DISULFONE-FUNCTIONALIZED MOLECULES
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP0594697A1

  公开（公告）日：1994-05-04
• ADDITIVES FOR DYE-SENSITIZED SOLAR CELLS
  申请人：Merck Patent GmbH

  公开号：EP2820105A1

  公开（公告）日：2015-01-07